Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 27 | 2023 | 2249 | 4.230 |
Why?
|
DNA Repair | 15 | 2023 | 2046 | 1.870 |
Why?
|
Prostatic Neoplasms | 32 | 2023 | 11126 | 1.590 |
Why?
|
DNA Repair-Deficiency Disorders | 2 | 2023 | 29 | 1.550 |
Why?
|
DNA Damage | 10 | 2023 | 2432 | 1.320 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 8 | 2023 | 105 | 1.150 |
Why?
|
Muscles | 7 | 2023 | 1614 | 1.060 |
Why?
|
Brachytherapy | 8 | 2021 | 1248 | 0.890 |
Why?
|
Anus Neoplasms | 4 | 2024 | 332 | 0.890 |
Why?
|
Ataxia Telangiectasia | 1 | 2023 | 112 | 0.880 |
Why?
|
Urinary Bladder | 5 | 2023 | 1173 | 0.830 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2021 | 203 | 0.780 |
Why?
|
DNA Nucleotidyltransferases | 4 | 2010 | 193 | 0.770 |
Why?
|
Carcinoma, Transitional Cell | 3 | 2022 | 808 | 0.700 |
Why?
|
Cystectomy | 8 | 2023 | 686 | 0.690 |
Why?
|
Radiosurgery | 3 | 2024 | 1329 | 0.680 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 647 | 0.660 |
Why?
|
Prostatectomy | 7 | 2021 | 1890 | 0.650 |
Why?
|
Neoplasm Invasiveness | 14 | 2023 | 3616 | 0.640 |
Why?
|
Cisplatin | 10 | 2023 | 1662 | 0.620 |
Why?
|
Antineoplastic Agents | 11 | 2023 | 13693 | 0.620 |
Why?
|
Mastectomy, Segmental | 2 | 2013 | 956 | 0.610 |
Why?
|
Gene Amplification | 1 | 2021 | 1063 | 0.590 |
Why?
|
Allergy and Immunology | 1 | 2018 | 169 | 0.590 |
Why?
|
Retinoblastoma | 2 | 2014 | 317 | 0.500 |
Why?
|
Recombination, Genetic | 3 | 2010 | 1586 | 0.500 |
Why?
|
Radiation Oncology | 3 | 2018 | 555 | 0.490 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 806 | 0.480 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 144 | 0.430 |
Why?
|
Neoplasms, Second Primary | 4 | 2023 | 1062 | 0.430 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 890 | 0.420 |
Why?
|
Bacterial Proteins | 5 | 2010 | 3854 | 0.420 |
Why?
|
Genomics | 7 | 2023 | 5717 | 0.420 |
Why?
|
Fanconi Anemia | 1 | 2014 | 319 | 0.400 |
Why?
|
Sesquiterpenes | 2 | 2023 | 177 | 0.390 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3554 | 0.390 |
Why?
|
Mutation | 18 | 2023 | 29786 | 0.380 |
Why?
|
Androgen Antagonists | 7 | 2022 | 1377 | 0.370 |
Why?
|
DNA | 6 | 2024 | 7294 | 0.360 |
Why?
|
Prostate | 7 | 2022 | 1775 | 0.360 |
Why?
|
Salvage Therapy | 1 | 2016 | 1275 | 0.360 |
Why?
|
Urologic Neoplasms | 3 | 2019 | 318 | 0.350 |
Why?
|
Prostate-Specific Antigen | 7 | 2022 | 2494 | 0.340 |
Why?
|
Deglutition | 1 | 2010 | 198 | 0.340 |
Why?
|
Humans | 95 | 2024 | 744366 | 0.340 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4034 | 0.330 |
Why?
|
Mutation, Missense | 1 | 2018 | 2566 | 0.330 |
Why?
|
Neoplasms | 7 | 2024 | 21696 | 0.320 |
Why?
|
Laryngeal Neoplasms | 1 | 2012 | 512 | 0.320 |
Why?
|
BRCA2 Protein | 5 | 2023 | 794 | 0.320 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 11525 | 0.320 |
Why?
|
Germ-Line Mutation | 4 | 2022 | 1788 | 0.310 |
Why?
|
Poly(ADP-ribose) Polymerases | 2 | 2023 | 440 | 0.310 |
Why?
|
Models, Molecular | 6 | 2014 | 5451 | 0.300 |
Why?
|
Computational Biology | 2 | 2019 | 3519 | 0.300 |
Why?
|
Genes, BRCA2 | 4 | 2023 | 618 | 0.290 |
Why?
|
Education, Medical | 1 | 2018 | 1722 | 0.280 |
Why?
|
Cell Cycle Proteins | 1 | 2018 | 3464 | 0.280 |
Why?
|
Watchful Waiting | 3 | 2019 | 492 | 0.280 |
Why?
|
Patient Preference | 1 | 2013 | 889 | 0.270 |
Why?
|
Speech | 1 | 2010 | 541 | 0.270 |
Why?
|
Cell Cycle | 1 | 2014 | 2967 | 0.260 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2018 | 1771 | 0.260 |
Why?
|
Protein Multimerization | 1 | 2010 | 971 | 0.260 |
Why?
|
Borrelia burgdorferi | 1 | 2007 | 180 | 0.250 |
Why?
|
Breast Neoplasms | 4 | 2019 | 20824 | 0.250 |
Why?
|
DNA Mismatch Repair | 2 | 2018 | 426 | 0.250 |
Why?
|
BRCA1 Protein | 4 | 2023 | 1149 | 0.250 |
Why?
|
Male | 54 | 2023 | 350115 | 0.250 |
Why?
|
Disease-Free Survival | 7 | 2023 | 6896 | 0.250 |
Why?
|
Immunotherapy | 5 | 2024 | 4446 | 0.240 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2021 | 547 | 0.230 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2023 | 5172 | 0.230 |
Why?
|
Biomedical Research | 1 | 2018 | 3309 | 0.220 |
Why?
|
Lung Neoplasms | 3 | 2024 | 13104 | 0.220 |
Why?
|
Neoplasm Staging | 11 | 2023 | 11031 | 0.220 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3590 | 0.210 |
Why?
|
Seminoma | 1 | 2023 | 139 | 0.210 |
Why?
|
Recombinases | 2 | 2013 | 67 | 0.200 |
Why?
|
Combined Modality Therapy | 6 | 2024 | 8642 | 0.200 |
Why?
|
DNA, Bacterial | 1 | 2007 | 1465 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2023 | 9240 | 0.200 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2013 | 876 | 0.200 |
Why?
|
Cell Line, Tumor | 5 | 2021 | 16690 | 0.200 |
Why?
|
Organs at Risk | 2 | 2014 | 346 | 0.200 |
Why?
|
Radiotherapy | 2 | 2019 | 1533 | 0.200 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2021 | 705 | 0.190 |
Why?
|
Radiotherapy Dosage | 4 | 2019 | 2879 | 0.190 |
Why?
|
DNA-Binding Proteins | 3 | 2020 | 9647 | 0.190 |
Why?
|
Aged | 33 | 2023 | 163288 | 0.190 |
Why?
|
Papillomavirus Infections | 2 | 2024 | 1587 | 0.190 |
Why?
|
Survival Analysis | 6 | 2020 | 10252 | 0.180 |
Why?
|
Retrospective Studies | 22 | 2024 | 77460 | 0.170 |
Why?
|
Ki-67 Antigen | 1 | 2021 | 644 | 0.170 |
Why?
|
Genes, Neoplasm | 2 | 2017 | 376 | 0.160 |
Why?
|
Ultraviolet Rays | 2 | 2023 | 1060 | 0.160 |
Why?
|
GTP Phosphohydrolases | 1 | 2021 | 508 | 0.160 |
Why?
|
Neoplasm Proteins | 3 | 2020 | 3707 | 0.160 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 109 | 0.160 |
Why?
|
Treatment Outcome | 14 | 2023 | 63107 | 0.160 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 501 | 0.160 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 221 | 0.160 |
Why?
|
DNA Polymerase III | 1 | 2018 | 55 | 0.160 |
Why?
|
Serine | 2 | 2013 | 826 | 0.160 |
Why?
|
Microsatellite Instability | 2 | 2018 | 684 | 0.160 |
Why?
|
DNA Copy Number Variations | 3 | 2021 | 1941 | 0.150 |
Why?
|
DNA Polymerase II | 1 | 2018 | 107 | 0.150 |
Why?
|
Signal Transduction | 3 | 2023 | 23404 | 0.150 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2019 | 594 | 0.150 |
Why?
|
Prognosis | 12 | 2020 | 29060 | 0.150 |
Why?
|
Testicular Neoplasms | 1 | 2023 | 806 | 0.150 |
Why?
|
Carcinoma | 2 | 2019 | 2375 | 0.150 |
Why?
|
Head and Neck Neoplasms | 1 | 2010 | 2736 | 0.140 |
Why?
|
Kallikreins | 1 | 2018 | 258 | 0.140 |
Why?
|
INDEL Mutation | 1 | 2017 | 279 | 0.140 |
Why?
|
Travel | 2 | 2021 | 788 | 0.140 |
Why?
|
Female | 28 | 2022 | 380193 | 0.130 |
Why?
|
Aged, 80 and over | 14 | 2021 | 57776 | 0.130 |
Why?
|
Dimerization | 2 | 2008 | 895 | 0.130 |
Why?
|
DNA Mutational Analysis | 3 | 2018 | 4185 | 0.130 |
Why?
|
Middle Aged | 27 | 2021 | 213390 | 0.130 |
Why?
|
Microsatellite Repeats | 1 | 2017 | 802 | 0.130 |
Why?
|
Microtubule-Associated Proteins | 1 | 2020 | 1085 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 332 | 0.130 |
Why?
|
Databases, Factual | 6 | 2019 | 7730 | 0.120 |
Why?
|
Follow-Up Studies | 8 | 2021 | 39052 | 0.120 |
Why?
|
Neuropeptides | 1 | 2020 | 942 | 0.120 |
Why?
|
Neuroendocrine Tumors | 1 | 2020 | 594 | 0.120 |
Why?
|
Radiation Tolerance | 1 | 2016 | 486 | 0.120 |
Why?
|
Quality of Life | 2 | 2013 | 12802 | 0.120 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 1692 | 0.120 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 602 | 0.120 |
Why?
|
Protein Conformation | 4 | 2014 | 4010 | 0.120 |
Why?
|
Colon, Sigmoid | 1 | 2014 | 120 | 0.120 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1879 | 0.120 |
Why?
|
DNA Cleavage | 1 | 2013 | 58 | 0.110 |
Why?
|
Stromal Cells | 1 | 2019 | 1355 | 0.110 |
Why?
|
SEER Program | 4 | 2019 | 1507 | 0.110 |
Why?
|
Biocatalysis | 1 | 2013 | 167 | 0.110 |
Why?
|
Acids | 1 | 2013 | 127 | 0.110 |
Why?
|
Genomic Instability | 1 | 2017 | 695 | 0.110 |
Why?
|
Carboplatin | 2 | 2015 | 801 | 0.110 |
Why?
|
Mice, SCID | 1 | 2018 | 2716 | 0.110 |
Why?
|
Crystallography, X-Ray | 2 | 2008 | 2012 | 0.110 |
Why?
|
Protein Structure, Quaternary | 2 | 2010 | 436 | 0.110 |
Why?
|
Mutant Proteins | 2 | 2013 | 500 | 0.110 |
Why?
|
Urothelium | 1 | 2014 | 277 | 0.100 |
Why?
|
Neoadjuvant Therapy | 5 | 2023 | 2727 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2013 | 9955 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 2020 | 6364 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2018 | 3595 | 0.100 |
Why?
|
Genome | 1 | 2020 | 1807 | 0.100 |
Why?
|
Immunohistochemistry | 3 | 2021 | 11366 | 0.100 |
Why?
|
Cohort Studies | 9 | 2020 | 40559 | 0.100 |
Why?
|
Cell Division | 1 | 2018 | 4569 | 0.100 |
Why?
|
Evaluation Studies as Topic | 1 | 2013 | 1681 | 0.100 |
Why?
|
Hydroxyurea | 1 | 2012 | 289 | 0.100 |
Why?
|
Protein Kinases | 1 | 2018 | 1640 | 0.090 |
Why?
|
Prospective Studies | 9 | 2024 | 53290 | 0.090 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2015 | 484 | 0.090 |
Why?
|
Ultracentrifugation | 1 | 2010 | 182 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 604 | 0.090 |
Why?
|
Arginine | 1 | 2013 | 944 | 0.090 |
Why?
|
Radiotherapy, Conformal | 1 | 2013 | 548 | 0.090 |
Why?
|
Gene Expression Profiling | 3 | 2020 | 9445 | 0.090 |
Why?
|
Rectum | 1 | 2014 | 904 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2017 | 1524 | 0.080 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 523 | 0.080 |
Why?
|
Binding Sites | 2 | 2008 | 6111 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 3143 | 0.080 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2012 | 640 | 0.080 |
Why?
|
DNA Methylation | 2 | 2019 | 4285 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2012 | 624 | 0.080 |
Why?
|
Promoter Regions, Genetic | 1 | 2019 | 5867 | 0.080 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1939 | 0.080 |
Why?
|
Radiometry | 1 | 2013 | 800 | 0.080 |
Why?
|
Substrate Specificity | 2 | 2013 | 1802 | 0.080 |
Why?
|
Oligonucleotides | 1 | 2010 | 572 | 0.070 |
Why?
|
Fluorouracil | 1 | 2012 | 1619 | 0.070 |
Why?
|
Nucleic Acid Conformation | 2 | 2010 | 913 | 0.070 |
Why?
|
Crystallization | 1 | 2008 | 525 | 0.070 |
Why?
|
Cell Line | 2 | 2018 | 16000 | 0.070 |
Why?
|
Germ Cells | 2 | 2022 | 631 | 0.070 |
Why?
|
Risk Assessment | 6 | 2020 | 23336 | 0.070 |
Why?
|
Genome, Human | 2 | 2018 | 4420 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 4262 | 0.070 |
Why?
|
Catalysis | 1 | 2008 | 762 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2019 | 8432 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2019 | 3480 | 0.070 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1624 | 0.070 |
Why?
|
Visual Acuity | 1 | 2014 | 2530 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2530 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5534 | 0.060 |
Why?
|
Paclitaxel | 1 | 2012 | 1708 | 0.060 |
Why?
|
Survival Rate | 4 | 2020 | 12788 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2021 | 7882 | 0.060 |
Why?
|
Logistic Models | 4 | 2020 | 13409 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5223 | 0.060 |
Why?
|
Radiography | 1 | 2014 | 7023 | 0.060 |
Why?
|
Androgens | 2 | 2021 | 1281 | 0.060 |
Why?
|
DNA Replication | 2 | 2022 | 1399 | 0.060 |
Why?
|
Mice, Knockout | 1 | 2018 | 14561 | 0.060 |
Why?
|
Palliative Care | 1 | 2017 | 3493 | 0.050 |
Why?
|
Propensity Score | 2 | 2021 | 1781 | 0.050 |
Why?
|
Adult | 10 | 2021 | 214052 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
Ribonuclease H | 1 | 2022 | 45 | 0.050 |
Why?
|
Sequence Alignment | 1 | 2007 | 2256 | 0.050 |
Why?
|
Time Factors | 3 | 2018 | 40075 | 0.050 |
Why?
|
Genome, Bacterial | 1 | 2007 | 760 | 0.050 |
Why?
|
Animals | 5 | 2021 | 168768 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2022 | 98 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6773 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5135 | 0.050 |
Why?
|
Orchiectomy | 1 | 2023 | 474 | 0.050 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3611 | 0.050 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12244 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2009 | 1453 | 0.050 |
Why?
|
BCG Vaccine | 1 | 2023 | 369 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12356 | 0.050 |
Why?
|
Age Factors | 2 | 2017 | 18373 | 0.050 |
Why?
|
Cyclin E | 1 | 2020 | 172 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2020 | 2949 | 0.040 |
Why?
|
Protein Structure, Tertiary | 1 | 2007 | 3848 | 0.040 |
Why?
|
Urethra | 1 | 2021 | 408 | 0.040 |
Why?
|
Deoxycytidine | 1 | 2023 | 826 | 0.040 |
Why?
|
Catalytic Domain | 2 | 2013 | 698 | 0.040 |
Why?
|
Geography | 1 | 2021 | 669 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2460 | 0.040 |
Why?
|
Risk Factors | 5 | 2019 | 72296 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4839 | 0.040 |
Why?
|
Pelvis | 1 | 2022 | 730 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 4 | 2022 | 17446 | 0.040 |
Why?
|
Mice | 2 | 2021 | 81201 | 0.040 |
Why?
|
Time-Lapse Imaging | 1 | 2018 | 195 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2019 | 793 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6539 | 0.040 |
Why?
|
Drug Synergism | 1 | 2021 | 1794 | 0.040 |
Why?
|
Allelic Imbalance | 1 | 2017 | 77 | 0.040 |
Why?
|
Tumor Burden | 1 | 2022 | 1915 | 0.040 |
Why?
|
Probability | 1 | 2022 | 2506 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4851 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2020 | 749 | 0.030 |
Why?
|
Anal Canal | 1 | 2019 | 376 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 350 | 0.030 |
Why?
|
Gene Dosage | 1 | 2020 | 1252 | 0.030 |
Why?
|
Infant | 2 | 2014 | 35134 | 0.030 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 388 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 15160 | 0.030 |
Why?
|
Child, Preschool | 2 | 2014 | 41005 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2007 | 13814 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2020 | 2971 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2020 | 2887 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1677 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2007 | 18111 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2017 | 781 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1038 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2021 | 1928 | 0.030 |
Why?
|
Genetic Markers | 1 | 2019 | 2634 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1366 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2022 | 1862 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15078 | 0.030 |
Why?
|
Molecular Imaging | 1 | 2018 | 828 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2018 | 1783 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20130 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2014 | 1202 | 0.020 |
Why?
|
Gene Silencing | 1 | 2017 | 1539 | 0.020 |
Why?
|
Incidence | 2 | 2022 | 20952 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2019 | 3207 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5953 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1372 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2020 | 2585 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1707 | 0.020 |
Why?
|
Endometrial Neoplasms | 1 | 2018 | 1351 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2013 | 2556 | 0.020 |
Why?
|
RNA-Binding Proteins | 1 | 2017 | 1903 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2018 | 2182 | 0.020 |
Why?
|
Observer Variation | 1 | 2014 | 2593 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5524 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2864 | 0.020 |
Why?
|
Cause of Death | 1 | 2018 | 3582 | 0.020 |
Why?
|
Neutrophils | 1 | 2019 | 3721 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3020 | 0.020 |
Why?
|
Decision Making | 1 | 2021 | 3888 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9688 | 0.020 |
Why?
|
Odds Ratio | 1 | 2019 | 9849 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2021 | 10483 | 0.020 |
Why?
|
United States | 3 | 2018 | 69872 | 0.020 |
Why?
|
Kinetics | 1 | 2013 | 6476 | 0.020 |
Why?
|
Mutagenesis | 1 | 2009 | 1264 | 0.020 |
Why?
|
Genotype | 1 | 2018 | 12952 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2015 | 3799 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2010 | 3702 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15221 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18034 | 0.010 |
Why?
|
Lung | 1 | 2021 | 9857 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2017 | 13035 | 0.010 |
Why?
|
Phosphorylation | 1 | 2013 | 8436 | 0.010 |
Why?
|
Disease Progression | 1 | 2018 | 13286 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2019 | 10183 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 19905 | 0.010 |
Why?
|
Phenotype | 1 | 2018 | 16367 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15520 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9584 | 0.010 |
Why?
|
Young Adult | 1 | 2013 | 56429 | 0.000 |
Why?
|
Child | 1 | 2013 | 77709 | 0.000 |
Why?
|
Adolescent | 1 | 2013 | 85779 | 0.000 |
Why?
|